» Articles » PMID: 31732375

Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel

Abstract

Bleeding is the most common complication of anticoagulant use. The evaluation and management of the bleeding patient is a core competency of emergency medicine. As the prevalence of patients receiving anticoagulant agents and variety of anticoagulants with different mechanisms of action, pharmacokinetics, indications, and corresponding reversal agents increase, physicians and other clinicians working in the emergency department require a current and nuanced understanding of how best to assess, treat, and reverse anticoagulated patients. In this project, we convened an expert panel to create a consensus decision tree and framework for assessment of the bleeding patient receiving an anticoagulant, as well as use of anticoagulant reversal or coagulation factor replacement, and to address controversies and gaps relevant to this topic. To support decision tree interpretation, the panel also reached agreement on key definitions of life-threatening bleeding, bleeding at a critical site, and emergency surgery or urgent invasive procedure. To reach consensus recommendations, we used a structured literature review and a modified Delphi technique by an expert panel of academic and community physicians with training in emergency medicine, cardiology, hematology, internal medicine/thrombology, pharmacology, toxicology, transfusion medicine and hemostasis, neurology, and surgery, and by other key stakeholder groups.

Citing Articles

Assessing the effectiveness of a rural distribution program in reducing time to prothrombin complex concentrate administration in patients taking warfarin.

Polzin A, Stroman J, Schaap R, Baird R, Sturdevant D, Gurumoorthy A Hosp Pract (1995). 2025; 53(1):2455930.

PMID: 39825620 PMC: 11885032. DOI: 10.1080/21548331.2025.2455930.


Urgent Reversal of Direct Oral Anticoagulants in Critical and Life-Threatening Bleeding: A Multidisciplinary Expert Consensus.

Rodrigues A, Goncalves L, Gregorio T, Baldaia C, Santo G, Gouveia J J Clin Med. 2024; 13(22).

PMID: 39597986 PMC: 11595216. DOI: 10.3390/jcm13226842.


3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors.

Hays W, Billups K, Nicholson J, Bailey A, Gregory H, Weeda E J Thromb Thrombolysis. 2024; 58(2):276-283.

PMID: 39467897 PMC: 11885330. DOI: 10.1007/s11239-024-03052-4.


Drug Interactions between Androgen Receptor Axis-Targeted Therapies and Antithrombotic Therapies in Prostate Cancer: Delphi Consensus.

Leblanc K, Edwards S, Dranitsaris G, Leong D, Carrier M, Malone S Cancers (Basel). 2024; 16(19).

PMID: 39409956 PMC: 11475820. DOI: 10.3390/cancers16193336.


Efficacy and Safety of Andexanet Alfa Versus Four Factor Prothrombin Complex Concentrate for Emergent Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage: A Systematic Review and Meta-Analysis.

Sarhan K, Mohamed R, Elmahdi R, Mohsen Y, Elsayed A, Zayed D Neurocrit Care. 2024; .

PMID: 39379749 DOI: 10.1007/s12028-024-02130-y.


References
1.
Boyack I, Opsha O . Coagulopathic hemorrhage with use of synthetic cannabinoids. Am J Emerg Med. 2018; 37(2):374.e3-374.e4. DOI: 10.1016/j.ajem.2018.10.016. View

2.
Agnelli G, Buller H, Cohen A, Curto M, Gallus A, Johnson M . Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2012; 368(8):699-708. DOI: 10.1056/NEJMoa1207541. View

3.
Eikelboom J, Mehta S, Anand S, Xie C, Fox K, Yusuf S . Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006; 114(8):774-82. DOI: 10.1161/CIRCULATIONAHA.106.612812. View

4.
Honda Y, Furugohri T, Morishima Y . Tranexamic Acid Failed to Reverse the Anticoagulant Effect and Bleeding by an Oral Direct Factor Xa Inhibitor Edoxaban. Pharmacology. 2017; 101(1-2):92-95. DOI: 10.1159/000484172. View

5.
Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. DOI: 10.1056/NEJMoa1107039. View